TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03376932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP/SAL
Description: FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP/SAL
Description: FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be delivered as a rescue medication via MDI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be delivered as a rescue medication via MDI.
Study: NCT03070561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sublingual film with peanut extract
Study: NCT02528123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxymetacaine 0.5%
Description: Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
Study: NCT03376932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be delivered as a rescue medication via MDI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be delivered as a rescue medication via MDI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DISKUS DPI
Description: The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DISKUS DPI
Description: The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESPIMAT inhaler
Description: The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RESPIMAT inhaler
Description: The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler
Description: Albuterol/salbutamol will be delivered as a rescue medication via MDI.
Study: NCT01747785

Intervention type: OTHER
Intervention: Cardiac rehabilitation
Description: Aerobic cardiac exercise training will be provided over the 12 week study duration.
Study: NCT03376932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler
Description: Albuterol/salbutamol will be delivered as a rescue medication via MDI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metered Dose Inhaler
Description: Albuterol/salbutamol will be delivered as a rescue medication via MDI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metered Dose Inhaler
Description: Albuterol/salbutamol will be delivered as a rescue medication via MDI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Inhaler System
Description: The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Inhaler System
Description: The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.
Study: NCT03419429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.
Study: NCT02528123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine 0.4%
Description: Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
Study: NCT01747785

Intervention type: OTHER
Intervention: Myocardial deformation imaging
Description: A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
Study: NCT03419429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDTA
Description: EDTA is a demineralizing agent used for root surface conditioning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDTA
Description: EDTA is a demineralizing agent used for root surface conditioning.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusive membrane
Description: Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusive membrane
Description: Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified perforated membrane
Description: Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified perforated membrane
Description: Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration
Study: NCT03401437

Intervention type: BEHAVIORAL
Intervention: SF-36
Description: Evaluation of the quality of life with an auto-questionnaire validated, with 8 dimensions: physical activity ; limitations due to physical condition; physical pain; perceived health; vitality; life and relationship with others; limitations due to physical condition; psychic health as well as the assessment of perceived health compared to a year ago. Evaluation done pre-operatively, at M1 and M3
Study: NCT03600818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab-matching placebo
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone-matching placebo
Description: Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
Study: NCT00915239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40 mg pantoprazole once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo once daily for 28 days
Study: NCT01747785

Intervention type: OTHER
Intervention: Myocardial deformation imaging
Description: A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.

Intervention type: OTHER
Intervention: Cardiopulmonary exercise test
Description: The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.

Intervention type: OTHER
Intervention: Cardiopulmonary exercise test
Description: The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
Study: NCT01181102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edoxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin sodium
Study: NCT04753047

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00741455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \> 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg/day on days 5, 6, and 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2/d IV over 30 minutes on days -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1 g/m2/d IV on days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
Study: NCT02799134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Study: NCT00788034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA21004
Description: 5 or 10 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT03242460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG
Description: Pomalidomide 4mg Days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20mg
Description: Dexamethasone 20mg Days 1, 8, 15, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 400mg
Description: Cyclophosphamide 400mg Days 1, 8, 15
Study: NCT04671030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine and Glycopyrrolate
Description: Intravenous followed by transdermal administration of the two drug combination.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Iontophoresis
Description: Application of direct current to skin using an FDA-approved device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: Application of direct current to skin using an FDA-approved device
Study: NCT02567318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-scan
Description: Magnetic resonance imaging scan of the brain
Study: NCT03134443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Andrographolide sulfonate
Description: Routine treatment for acute tonsillitis + Xiyanping injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Andrographolide sulfonate simulation
Description: Routine treatment for acute tonsillitis + Xiyanping injection simulation
Study: NCT03869203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Description: The patients in the ERAS group were given a pre-treatment drug \[300 mg (gabapentin, Neurontin 300mg) and 10 mg oxycontin (oxycontin, Oxycontin CR 10mg) and 2 mg prednisolone (prednisolone 10 mg, Solondo 5mg)\] on the evening before surgery. And pre-operative fasting should not exceed 6 hours, and clear liquid fasting should not exceed 2 hours. In addition, 400 ml of oral carbohydrate should be taken 2 to 4 hours before surgery to ensure adequate blood sugar and encourage regular diet (light meal) as soon as possible within a tolerable range after surgery. The initial pain after surgery is actively controlled by oral drugs such as celebrex and IR codon, and injections such as tramadol and demerol. On the first postoperative day, the urinary catheter is removed and CPM (continuous passive motion) rehabilitation is started.
Study: NCT04414306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person cancer screening education
Description: Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational video and website module
Description: Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational video
Description: Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Message from healthcare system and online educational video and website module
Description: Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
Study: NCT03642626

Intervention type: DRUG
Intervention: KYMRIAH
Description: FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells

Intervention type: DRUG
Intervention: KYMRIAH
Description: FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells

Intervention type: DRUG
Intervention: YESCARTA
Description: CD19-directed genetically modified autologous T cell immunotherapy
Study: NCT01226849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, rituximab, ifosphamide, etoposide, carboplatin
Description: Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
Study: NCT02555215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: administered orally
Study: NCT02928354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - AZD7594
Description: Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - AZD7594
Description: Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C - AZD7594
Description: Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
Study: NCT03451721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReady™ MR Conditional Defibrillation System
Description: Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
Study: NCT03237975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be the Expert for Your Own (BEYO)
Description: The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.~The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan.
Study: NCT03401437

Intervention type: BEHAVIORAL
Intervention: HAD
Description: Evaluation of anxiety and depression with a scale validated with 14 items assess between 0 and 3. Evaluation done pre-operatively and at M3.

Intervention type: OTHER
Intervention: ANSM
Description: Additional information requested by the ANSM (french National Agency for Medicines and Health Products Safety) following a materiovigilance report. Evaluation done pre-operatively and at M3.
Study: NCT02782442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Cognitive Training & PRIME
Description: The treatment condition-- 30-35 hours of CT over 16 weeks (\~2 hours per week) is a structured program of 20 hours of auditory processing exercises followed by 10 hours of social cognition exercises, combined with the personalized PRIME coaching application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Games Control & PRIME
Description: Computer games control condition which comes in the official PositScience wrapper. 30-35 hours of games over 16 weeks (\~2 hours per week), combined with the personalized PRIME coaching application.
Study: NCT02665533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg
Study: NCT03600818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone-matching placebo
Description: Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form:tablets Route of administration: oral administration